Chicago IL 硬皮病临床试验
8项针对 硬皮病的研究正在 Chicago及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of AZD0120 in Autoimmune Diseases
招募中1/2 期
- Research Site, Chicago
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
招募中1 期
- The University of Chicago Medical Center, Chicago
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
招募中1 期
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
招募中2/3 期
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
招募中3 期
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
招募中2/3 期
- GSK Investigational Site, Chicago
Platform Clinical Study for Conquering Scleroderma
招募中2 期
- The University of Chicago Medical Center (UCMC), Chicago
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
招募中2 期
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
其他城市的 硬皮病试验
- New York City, NY10 项研究
- Ann Arbor, MI9 项研究
- Houston, TX8 项研究
- Los Angeles, CA7 项研究
- Boston, MA7 项研究
- Durham, NC7 项研究
- Baltimore, MD6 项研究
- Dallas, TX5 项研究
- New Orleans, LA5 项研究
- Miami, FL5 项研究
- Philadelphia, PA5 项研究
- Pittsburgh, PA5 项研究
Chicago的其他研究
- 乳腺癌59 项研究
- 非小细胞肺癌59 项研究
- 癌症（所有类型）51 项研究
- 前列腺癌45 项研究
- 肺癌43 项研究
- 转移性癌症42 项研究
- 肥胖症40 项研究
- 卵巢癌36 项研究
- 结直肠癌32 项研究
- 卒中31 项研究
- 头颈鳞状细胞癌29 项研究
- 超重29 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。